ArticleInflammation research : official journal of the European Histamine Research Society ... [et al.]2026
Epidermal retinoid starvation driven by AKR1B10 orchestrates barrier disruption and hyperinflammation in atopic dermatitis.
Article in Inflammation research : official journal of the European Histamine Research Society ... [et al.], 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundAtopic dermatitis (AD) is driven by a feed-forward loop of epidermal barrier disruption and immune dysregulation. Although retinoic acid (RA) signaling is indispensable for epidermal homeostasis and terminal differentiation, the molecular mechanisms underlying its functional exhaustion in eczematous lesions remain incompletely elucidated. To investigate whether the aldo-keto reductase AKR1B10 mediates intracellular RA depletion and epidermal dysfunction in AD, and to evaluate the therapeutic potential of topical aldo-keto reductase inhibition.
methodsWe integrated single-cell RNA sequencing (scRNA-seq), bulk RNA-seq, and spatial transcriptomic datasets to identify AKR1B10 as a severity-associated metabolic candidate. In vitro, we performed siRNA-mediated knockdown and plasmid-based overexpression of AKR1B10 in HaCaT and primary human keratinocytes (NHEKs), complemented by RAR antagonist (AGN193109) blockade and exogenous atRA rescue. In vivo, we tested topical fidarestat in an MC903/OVA-induced AD mouse model.
resultsAKR1B10 was significantly upregulated in AD keratinocytes, preferentially enriched in the stratum spinosum, and positively correlated with patient SCORAD scores (r = 0.70). AKR1B10 overexpression depleted intracellular atRA (validated by targeted LC-MS/MS), downregulated barrier proteins (FLG, KRT10, CLDN1), and induced pro-inflammatory mediators (IL-6, IL-8, CXCL1). AGN blockade abrogated the protective effects of AKR1B10 knockdown, while exogenous atRA rescued the overexpression phenotype. Topical fidarestat restored cutaneous atRA availability and RA target gene expression (CYP26A1, CRABP2), repaired epidermal architecture, and attenuated AD-like inflammation in vivo.
conclusionAKR1B10 acts as a localized enzymatic sink that depletes intracellular RA pools, linking metabolic dysregulation to barrier disruption and hyperinflammation in AD. Topical aldo-keto reductase inhibition represents a promising, mechanistically grounded barrier-restorative strategy, although definitive AKR1B10-specific in vivo validation requires further study.
Indexed as
Identifiers
42862354What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.